← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Charles River had revenue -0.9% and net income -750.1%, but FCF still improved +3.4%.
The read at a glance✓ Audited against SEC data
- Growth — Revenue -0.9% to $4.02BWatch
- Profitability — Net income -750.1% to -$0.14BWatch
- Cash quality — FCF +3.4% to $0.52BOK
- Margins — Operating margin -498 bps; net -414 bpsWatch
- Balance sheet — Debt -4.6%; equity -8.6%Note
- Insiders — 1 buy / 4 sellsWatch
Business
Charles River provides research models, drug discovery, non-clinical development, safety assessment, bioanalytical, and manufacturing-support services to pharmaceutical, biotechnology, academic, government, industrial, and medical-device customers.
Where the revenue comes from
Fiscal 2025, as CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reports it. History and quarterly detail are in the app.
- DSA$2.4B
- RMS$846.1M
- Manufacturing$766.4M
Leadership changes
From CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s own filings, the day they're filed.
- James C. Foster · Chief Executive Officer · departureeff. 2026-05-05
- Birgit Girshick · Chief Operating Officer · departureeff. 2026-05-05
- Michael G. Knell · President · appointment
Latest filings
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-08-05
- 8-K · Company announcement2026-05-11
- 10-Q · Quarterly report2026-05-07
- 8-K · Company announcement2026-05-07
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about CHARLES RIVER LABORATORIES INTERNATIONAL, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.